Atossa Therapeutics Inc
NASDAQ:ATOS
Atossa Therapeutics Inc
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company is headquartered in Seattle, Washington and currently employs 4 full-time employees. The company went IPO on 2012-11-08. The firm is focused on discovering and developing medicines for breast cancer, other breast conditions and Covid-19. Its Covid-19 drugs under development, including the AT-H201 program, is for severely ill patients on ventilators, and AT-301 COVID-19 is a nasal spray. Its nasal spray formulation AT-301 is being designed to contain ingredients that can potentially block SARS-CoV-2 viral entry gene proteins in nasal epithelial cells by interfering with spike protein activation by host proteases, by masking receptor binding domains via electrostatic mechanisms, and by providing a generalized mucoadhesive epithelial barrier. AT-H201 program is to develop a therapy to improve lung and function like a chemical vaccine. The company is also developing an oral formulation of Endoxifen to reduce mammographic breast density (MBD) and to prevent/reduce gynecomastia in prostate cancer patients starting androgen deprivation therapy.
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company is headquartered in Seattle, Washington and currently employs 4 full-time employees. The company went IPO on 2012-11-08. The firm is focused on discovering and developing medicines for breast cancer, other breast conditions and Covid-19. Its Covid-19 drugs under development, including the AT-H201 program, is for severely ill patients on ventilators, and AT-301 COVID-19 is a nasal spray. Its nasal spray formulation AT-301 is being designed to contain ingredients that can potentially block SARS-CoV-2 viral entry gene proteins in nasal epithelial cells by interfering with spike protein activation by host proteases, by masking receptor binding domains via electrostatic mechanisms, and by providing a generalized mucoadhesive epithelial barrier. AT-H201 program is to develop a therapy to improve lung and function like a chemical vaccine. The company is also developing an oral formulation of Endoxifen to reduce mammographic breast density (MBD) and to prevent/reduce gynecomastia in prostate cancer patients starting androgen deprivation therapy.
Cost Discipline: Atossa reduced 2024 operating expenses to $27.6 million from $31.4 million in 2023, mainly through lower R&D and G&A costs.
Cash Position: The company ended 2024 with $71.1 million in cash and cash equivalents, providing a strong financial runway.
Lead Program Focus: Z-endoxifen remains the lead candidate, with a renewed focus on metastatic breast cancer as the initial target for expedited development and approval.
Clinical Data: Phase I and II studies of Z-endoxifen showed promising efficacy and tolerability, including a 26% clinical benefit rate and improved progression-free survival in difficult-to-treat patients.
Regulatory Plans: Atossa plans to consult with key opinion leaders and the FDA over the next 4–6 months to finalize the registrational trial design for Z-endoxifen in metastatic breast cancer.
Future Outlook: The company aims for a US FDA-focused approach in 2025 and may pursue global markets in 2026.
